{
    "pmcid": "8967979",
    "summary": "The paper titled \"Short-Term Instantaneous Prophylaxis and Efficient Treatment Against SARS-CoV-2 in hACE2 Mice Conferred by an Intranasal Nanobody (Nb22)\" explores the development and application of a nanobody, Nb22, for the prevention and treatment of SARS-CoV-2, particularly the Delta variant. Here is a detailed summary focusing on the role of nanobodies in designing SARS-CoV-2 binders:\n\n### Key Insights on Nanobodies:\n\n1. **Nanobody Characteristics**:\n   - Nanobodies are single-domain antibodies derived from camelid heavy-chain antibodies, known for their small size, stability, and ease of production.\n   - They exhibit high thermostability, retaining activity even after exposure to high temperatures (e.g., 70\u00b0C for 1 hour) and multiple freeze-thaw cycles.\n\n2. **Nb22 Development**:\n   - Nb22 was isolated from an alpaca immunized with the SARS-CoV-2 spike protein.\n   - It demonstrated ultrapotent neutralization against the Delta variant with an IC50 value of 0.41 ng/ml (5.13 pM), significantly more potent than against the original WH01 strain.\n\n3. **Structural Insights**:\n   - Crystal structural analysis revealed that Nb22 binds to the receptor-binding domain (RBD) of the spike protein, effectively blocking its interaction with the human ACE2 receptor.\n   - The binding site of Nb22 overlaps with that of hACE2, preventing viral entry into host cells.\n   - The Delta variant mutations, particularly L452R, enhance the binding affinity of Nb22, contributing to its increased neutralization potency.\n\n4. **Mechanism of Action**:\n   - Nb22's binding to the RBD involves hydrogen bonds and hydrophobic interactions, with specific residues in the complementarity-determining regions (CDRs) playing crucial roles.\n   - The L452R mutation in the Delta variant enhances interactions with Nb22, leading to increased binding affinity and neutralization potency.\n\n5. **In Vivo Efficacy**:\n   - Intranasal administration of Nb22 in hACE2 transgenic mice provided complete protection against Delta variant infection, both as a prophylactic and therapeutic agent.\n   - A single dose of Nb22 was effective for at least seven days, demonstrating potential for short-term instantaneous prophylaxis (STIP).\n\n6. **Advantages of Nanobodies**:\n   - Nanobodies like Nb22 can be produced at low cost in prokaryotic systems and are suitable for non-cold chain storage due to their stability.\n   - Their small size and stability make them ideal for intranasal or inhalable delivery, directly targeting the respiratory tract where SARS-CoV-2 replicates.\n\n7. **Potential Applications**:\n   - Nb22 could serve as a STIP agent, providing immediate protection against SARS-CoV-2, especially in unvaccinated individuals or those at high risk.\n   - Its long-lasting retention in the respiratory system suggests potential for weekly administration to maintain protection.\n\n8. **Implications for Future Research**:\n   - The structural insights from Nb22 can guide the design of pan-coronavirus vaccines and therapeutics.\n   - The study highlights the potential of nanobodies as a new class of therapeutics for rapid and effective response to emerging viral variants.\n\nIn conclusion, Nb22 represents a promising nanobody with ultrahigh potency against the Delta variant, offering a novel approach for both prophylaxis and treatment of SARS-CoV-2. Its stability, ease of production, and efficacy in intranasal delivery make it a strong candidate for addressing the unmet need for instantaneous protection against COVID-19.",
    "title": "Short-Term Instantaneous Prophylaxis and Efficient Treatment Against SARS-CoV-2 in hACE2 Mice Conferred by an Intranasal Nanobody (Nb22)"
}